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Abstract  
BRCA2-c.2808_2811del (3036delACAA) is one of the most reported germline mutations in non-
Ashkenazi breast cancer patients. We investigated its genetic origin in 51 Spanish carrier families 
that were genotyped with eleven 13q polymorphic markers. Three independent associated 
haplotypes were clearly distinguished accounting for 23 (WCL), 20 (ECL) and 6 families (SoS).  
Mutation age was estimated with the DMLE software in a range of 45-68 and 45-71 generations for 
WCL and ECL haplotypes, respectively. The most prevalent variants, c.2808_2811del and 
c.2803G>A, were located in a double-hairpin loop structure (c.2794-c.2825) predicted by Quikfold 
that was proposed as a mutational hotspot. To check this hypothesis, random mutagenesis was 
performed over a 923-bp fragment of BRCA2 and 86 DNA variants were characterized. 
Interestingly, three mutations reported in the mutation databases (c.2680G>A, c.2944del and 
c.2957dup) were replicated and 20 affected the same position with different nucleotide changes. 
Moreover, five variants were placed in the same hairpin-loop of c.2808_2811del, and one affected 
the same position (c.2808A>G). In conclusion, our results support that at least three different 
mutational events occurred to generate c.2808_2811del. Other highly prevalent DNA variants, 
such as BRCA1-c.68_69delAG and BRCA2-c.5946delT and c.8537delAG, are concentrated in hairpin-
loops suggesting that these structures may represent mutational hotspots. 
 
Introduction  
Hereditary predisposition accounts for 5–10% of all breast cancer cases [1;2], 15%-
20% of which are caused by mutations in the two major susceptibility genes BRCA1 (MIM# 
113705) and BRCA2 (MIM# 600185)[3]. More than 3,500 distinct DNA changes in BRCA1 and 
BRCA2 sequences have been characterized in the reference databases (The Breast Cancer 
Core Database, BIC database and the Universal Mutation Database, UMD) [4;5], which are 
spread throughout their entire coding and flanking intronic regions. Only a small number 
of DNA variations are predominant in some specific ethnic groups as a consequence of a 
founder effect originated in a common ancestor [6]. Spanish population has shown a 
specific distribution of founder mutations reflecting the existence of populations 
substructures in the Iberian Peninsula [7-10].  
According to the BIC database, c.2808_2811del (p.Ala938Profs*21) is the second 
most reported frameshift BRCA2 mutation, and the most prevalent mutation in Castilla y 
León (Spain) [9-11]. This mutation has been reported in almost all Western European 
countries [12] and in African women with premenopausal breast cancer [13]. Furthermore, 
the same mutation was found de novo in a breast cancer case that suggested that these 
BRCA2 nucleotides were a mutation hotspot [14].  
Knowledge of the molecular origin of a mutation is critical to the understanding of 
human disease and evolution. Mutations in humans may be caused by exogenous 
mutagens or endogenous mechanisms [15]. Mutation rates can vary substantially across 
genomic regions, so that they exceed the average rate at some extremely mutable sites 
(mutation hotspots) [16]. Moreover, a previous study of the secondary structure of the 
DNA showed that the most hypermutable bases of the TP53 tumor suppressor gene were 
located in stable DNA stem-loop arrangements [17]. In this study we set out to verify the 
presence of a possible unique founder effect of mutation c.2808_2811del or several 
independent mutational events occurred. This feature could be relevant in populations 
where the pre-screening of specific mutation panels is a cost-effective strategy prior the 
BRCA1/BRCA2 mutation scanning. To address this issue, we performed haplotype analysis 
in the region surrounding the BRCA2 gene in 51 carrier families and then, we estimated 
the mutation age according to each haplotype and its geographical distribution. 
Moreover, a DNA secondary structure prediction and a random mutagenesis experiment 
were performed to identify mutational hotspots. 
Materials and methods 
Patients  
Fifty-one unrelated families harboring BRCA2-c.2808_2811del from ten Spanish 
familial cancer centers were included in this study (Table 1). Patient data regarding age of 
diagnosis, current age or age at death, familial cancer history and geographical origin 
were collected. After written informed consent DNA samples were obtained from at least 
one affected member of each family. To date 23 c.2808_2811del families were identified in 
the IBGM laboratory after mutation scanning by CSGE (Conformational Sensitive Gel 
Electrophoresis) or HA-CAE (Heteroduplex Analysis by Capillary Array Electrophoresis) and 
confirmed by DNA sequencing as described elsewhere [18;19], but only sixteen affected 
families were included in this study. The screening of the rest of the patients was 
performed at the respective participant laboratories with different methods [10]. All 
mutation carriers from other laboratories were further confirmed at the IBGM.  The control 
population (75 anonymous and unrelated samples) used was obtained from the National 
DNA Bank, a collection of representative DNA samples of the Spanish population [20]. This 
study was approved by the Ethics committee of the Faculty of Medicine, University of 
Valladolid (Spain). 
Genotyping 
A total of 221 DNA samples representing 51 index cases, 95 family members and 75 
controls were typed with seven short tandem repeats (STRs) markers and four BRCA2 SNPs 
covering 1.34 Mb of chromosome 13 surrounding the c.2808_2811del BRCA2 mutation. 
Primer sequences, order of markers and physical distances among D13S260, D13S1699, 
D13S1698, D13S1697, D13S171, D13S1695 and D13S1694 were obtained from the 
Ensembl Genome Browser [21]. Polymerase chain reaction (PCR) products of STRs were 
generated using fluorescently labelled primers and subsequently electrophoresed on an 
ABI3130 sequencer (Applied Biosystems, Carlsbad, CA). Analysis was performed with the 
GeneMapper software v.3.7 (Applied Biosystems). Additionally, four BRCA2 SNPs: rs766173 
(c.865A>C), rs144848 (c.1114C>A), rs1801406 (c.3396A>G) and rs543304 (c.3807T>C) were 
typed by TaqMan assays in a 7500 Real Time PCR System (Applied Biosystems).  
Estimation of the mutation age 
We used the DMLE method [22] to estimate the mutation age. For this purpose, 
genotypes from 75 control individuals were submitted to the Phase v2.1 software to 
predict their haplotypes and estimate their frequencies (Supplemental Table S1). Then the 
phased data together with the inferred consensus carrier haplotype of 46 families and the 
two more prevalent haplotypes were independently introduced into the DMLE program, 
which calculated the mutation age. Population growth rate (r) was estimated by the 
formula t1=t0*egr, where g is the number of generations between two time points, t1 is 
the population size in 2010 (47 million) and t0 the ancestral population size. We used 
demographic data (INe: Population Census) [23] of two different years for t0: 1594 (~8.2 
million) or 1857 (~15 million), and g was estimated in 16.6 and 6.12 generations, 
respectively (considering 25 years per generation). Thus, r was estimated to be 0.124 and 
0.190 for 1594 and 1857 data, respectively.  
Random mutagenesis 
DNA of a control individual was amplified with Phusion Hot Start II High-Fidelity 
DNA Polymerase (Thermo Fisher Scientific, Waltham, MA) and primers containing a 5′-tail 
with a restriction site (underlined) either for EcoRI (Forward, 5' 
CACACAGAATTCAGAGGCAAAGAATCATACAAA 3') or for XhoI (Reverse, 5’ 
CACACACTCGAGTTGGAAAATAACATCTGAGGG 3’ (923 bp, c.2359-c.3281). After restriction 
enzyme digestion, insert and plasmid pBluescript II KS (Stratagene, La Jolla, CA) were 
ligated with the Fast-Link DNA Ligation Kit (Epicentre, Madison, WI) to transform 
Escherichia coli DH5α cells. Random mutagenesis was carried out with the Genemorph II 
EZClone Domain PCR mutagenesis kit (Agilent, Santa Clara, CA, USA). A PCR fragment 
(megaprimer) of 419 bp (c.2610-c.3028) was generated with nested BRCA2 primers 11E-
Fw, 5’-TTCAAAAATAACTGTCAATCC-3’, and 11F-Rev, 5’- TGAAGCTACCTCCAAAACTGT -3’, 
and the error prone Mutazyme-II DNA polymerase. Mutant PCR products serve as 
megaprimers for the EZClone reaction during which they are denatured and annealed to 
the original plasmid and extended with a high fidelity DNA polymerase. Then, the reaction 
was treated with DpnI, specific of methylated sequences, to eliminate the wild type 
plasmid that had been used as template. XL10-Gold ultracompetent cells (Agilent) were 
transformed with 1.5 μL of the EZClone reaction following the manufacturer’s protocol 
and were plated in LB-agar (Sigma-Aldrich, St. Louis, MO) plates with ampicillin 100 µg/ml, 
X-Gal 40 µg/ml and IPTG 0.1 mM. Seventy-five different colonies were picked individually 
and grown in liquid LB medium to purify plasmids with the Pure YieldTM Miniprep system 
(Promega, Madison, WI). Each clone was sequenced with BRCA2 primers 11E-Fw and 11F-
Rev to characterize the generated mutations. 
Sequence variation nomenclature 
Nomenclature of DNA variants followed the current guidelines of the Human 
Genome Variation Society (HGVS) [24] where nucleotide +1 is the A of the ATG-translation 
initiation codon of the BRCA2 cDNA sequence NM_000059.1. 
     
 
Results 
We have analyzed seven STR and four SNP markers in a total of 51 families, one of 
them of British origin, harbouring the c.2808_2811del mutation. Of these, at least two 
carrier relatives were tested in 37 families whilst only the index case was available in other 
14 families. Three different haplotypes were assigned to c.2808_2811del positive families; 
except for families CN-428 and CN-565 that could not be successfully classified (Figure 1). 
The geographical origin of the families and the corresponding haplotypes are shown in 
Figure 2. 
The most common haplotype was 157-144-163-225-A-A-A-T-195-253-234 (WCL 
haplotype) that accounted for 23 families, mainly from the West area of Castilla y León (8 
out of 9 SA-families; Figure 2). A second haplotype 159-148-175-225-A-A-G-T-195-253-236 
(ECL haplotype) was present in 20 pedigrees which included the largest sample from the 
East area of Castilla y León (12/16 carrier BU-families, Figure 2). Both haplotypes were very 
similar in their central core of 6 markers (Supplemental Table S1) but SNP c.3396A>G 
(rs1801406) was key to distinguish between them (“A”- WCL vs. “G”-ECL; Figure 1). Six 
other families, four of which were native from Southern Spain, were grouped in a third 
haplotype 157-144-163-221-A-C-A-T-[195 or 205]-251-228 (SoS haplotype).  
The most prevalent disease in carriers was breast cancer with 62 cases (Table 1), 
nine of which were bilateral and two were male BC cases. The medium age for BC cases 
was 43 years (range 26-82) whereas for OC was 58 years (49-69). Remarkably, 70 carriers 
(45 females and 25 males) were asymptomatic, although 60% of them (41/70) were under 
40 years old (Supplemental Table S2). It was noteworthy the different number of bilateral 
breast cancer cases observed (2/20 in WCL haplotype vs. 7/23 in ECL haplotype). 
Dating the origin of the mutation 
The results were population growth rate depending, and the oldest demographic 
data in Spain were in year 1594 but they were not reliable until 1857. Accordingly we used 
both records to calculate the Spanish population growth rate (r). The two main haplotypes 
and the complete set of 46 families with recognizable haplotype were submitted 
independently to DMLE analysis using the two r data (0.124 or 0.190; Supplemental Figure 
S1). Another key parameter in this software is the proportion of population sampled. The 
frequency of BRCA2 mutations in BOC patients is 1-3% [25], thus we obtained 0.000217 
assuming that 2% of 47 million people in Spain is a mutation carrier. In the whole set of 46 
Spanish families DMLE estimated a mutation age range between 72 and 110 generations 
(r=0.124) or 49-73 (r=0.190; Supplemental Figure S1). The 23 WCL families showed a range 
of 73-112 generations (r=0.124) or 45-68 generations (r=0.190) whereas the 20 ECL 
families resulted in a range of 67-105 generations (r=0.124) or 45-71 generations (r=0.190). 
Therefore, the mutation associated with ECL and WCL haplotypes could be dated on 
average around 55 generations ago (about 1375 years, in the VI-VII century during the 
Visigothic Kingdom; Supplemental Figure S1) when we used the most reliable estimation 
(0.190). Finally, mutation age of SoS haplotype could not be calculated as there had been 
collected only 6 families. However, all of them shared a common haplotype in 10 out of 11 
markers suggesting a more recent origin than the other two haplotypes.  
 
Random mutagenesis 
The absence of a unique ancestral haplotype as well as the identification of one de 
novo c.2808_2811del [14] suggested that this sequence was a mutation hotspot. It has 
been reported that mutations occur non-randomly since they are preferentially located in 
vulnerable stem-loops structures [17]. The DNA secondary structure of a 419-nucleotide 
region spanning this mutation was predicted with the Quikfold software [26;27]. We found 
a total of 14 stem-loops structures (Supplemental Figure S2) where 82 mutations of the 
databases were mapped (Supplemental Table S3). Forty-two out of them (51.2%) were 
positioned in single stranded loops or bulges that represent 41.6% of the analysed 
sequence (157/377 nucleotides, excluding primer sequences), and 7 variants were placed 
in the same loop of mutation c.2808_2811del within a complex double hairpin-loop 
structure, sustaining that this structure may be a mutation hotspot. 
With a view to investigating this hypothesis we designed a random mutagenesis 
experiment over a fragment surrounding c.2808_2811del. Seventy-five different clones 
were sequenced, 48 of which contained one (21 clones) or two or more (27 clones) DNA 
variants. We identified 86 different DNA changes, three of which were recurrent and were 
found twice in independent clones: c.2683G>A, c.2771A>G and c.2957dup (Supplemental 
Table S3). Seven mutations were single nucleotide deletions, one was a single nucleotide 
insertion (c.2957dup) and 78 were nucleotide substitutions. In addition, three mutations 
reported in the mutation databases were replicated in the random mutagenesis 
experiment: c.2680G>A, c.2944del and c.2957dup (twice, see above). Other 20 variants 
affected identical positions of databases variants although they consisted of different 
nucleotide changes. Of all changes produced, 53/86 (61.6%) were located into the stem-
loops predicted by Quikfold (Figure 3). Remarkably, random mutagenesis generated five 
mutations in the double hairpin-loop (#7) of the c.2808_2811del mutation, including a 
single nucleotide substitution in position 2808 (c.2808A>G). The highest incidence of 
mutations was found in hairpin 8 with 1 mutation every 1.1 nucleotide (Table 2). Hairpins 
4, 5, and 7 and inter-sequence 4 were also especially vulnerable to mutations with 1 
mutation every 1.7-1.8 nucleotides. 
 
Discussion 
Multiple origins of c.2808_2811del  
We found three different haplotypes linked to the mutation, which were correlated 
with the geographic distribution of families. Patients from Castilla y León were distributed 
into two haplotypes, which basically corresponded to the West and East areas of this 
region. Both areas had differences in the mutational spectrum of the BRCA genes [11;28], 
supporting two different genetic backgrounds and, therefore, two independent 
mutational events. The alternative hypothesis is the existence of a unique genetic origin 
that might have been originated either by a double recombination event between 
c.2808_2811del-rs1801406-rs543304 or a de novo mutation at nucleotide c.3396 (A to G, 
rs1801406; Figure 1). Both options seem unlikely, since, first, rs1801406 was only 588 
nucleotides downstream the deletion and 411 bp upstream rs543304 (totalling 999 bp), 
too close to undergo two crossovers, and, second, the mutation rate of single-nucleotide 
variants in the human genome has been recently estimated in 1.2x10-8 per base pair per 
generation [29], disregarding the hypothesis of a recent de novo event. A third haplotype 
(SoS) was distinguished in six families, four of which had origins in Southern provinces of 
Spain, suggesting a common founder effect. The deduced core haplotype (157-144-163-
221-A-C-A-T-[195/205]-251-228) shared alleles at ten out of eleven markers in the six 
families suggesting a more recent origin. Previous reports of a “de novo” mutation in a 
Dutch [14] and an African breast cancer patients without familial antecedents [13] give 
further support to multiple historical occurrences of c.2808_2811del. Indeed, one of our 
patients (a 32 year-old BC patient) was suspected to carry a de novo c.2808_2811del 
mutation, because none of the parents was a mutation carrier. Unfortunately, the 
haplotype construction cannot be performed because DNA patient sample was depleted. 
All the data presented here support that at least three different mutational events took 
place to originate c.2808_2811del, so that this sequence could be a mutation hotspot.  
Interestingly, c.2808_2811del was not previously reported in Sephardic Jewish 
breast cancer patients [30] despite almost 20% of Y-STR haplotypes of the Iberian 
Peninsula and Balearic Island are of Sephardic origin [31]. This might be due to the small 
sample size of the first report (only 16 patients) and the low frequency of the Sephardic 
ancestry in Castilla y León (East, 2.5%; West, 12.9%) where c.2808_2811del probably arose 
(major haplotypes ECL and WCL). Surprisingly, a putative founder BRCA1 mutation in 
Sephardic breast cancer patients, c.5123C>A (p.A1708E) [30], is precisely the most 
prevalent BRCA1 mutation in Castilla y León (12.2% of BRCA1+ families, data not shown) 
and the rest of Spain (11.3% on average) [9], suggesting that its genetic origin requires 
further investigation.  
 In earlier reports we estimated mutation age with a method based on the linkage 
disequilibrium due to recombination between the nearest recombinant marker and the 
mutation [28;32;33]. This calculation was impossible to conduct in c.2808_2811del families 
because the ancestral allele was more frequent in non-carrier chromosomes than in 
mutation-carriers in all cases. In this report, we estimated by DMLE that the mutation arose 
in Spain around 58 generations ago (1450 years), dating the mutation back to the VI 
century during the Visigothic Kingdom, with a range between 49 and 73 generations, and 
began to spread to the rest of Spain. Mutation age was previously estimated in ~80 
generations with the maximum likelihood method in eleven families from different 
countries, including Spain [12].  
Mutation hotspot 
It was reported that the most hypermutable nucleotides of the TP53 gene are 
located in secondary structures called hairpin-loops and bulges [17]. These structures 
contain regions of single-stranded DNA with unpaired or mispaired bases that are more 
vulnerable to mutation because they are exposed to endogenous (e.g. metabolites or DNA 
polymerase errors) or exogenous mutagens [15]. Furthermore, Quikfold data illustrate a 
complex structure that the polymerase might not copy properly (Figure 3) leading to 
different DNA changes around this position [26;34]. Moreover, the most reported 
sequence changes in the BIC and UMD mutation databases between nucleotides c.2610-
c.3028 were precisely this mutation (c.2808_2811del,199 records in the BIC and UMD 
databases) and c.2803G>A (151 records), both in the single stranded portion of this loop. 
Random mutagenesis created 5 different mutations in the predicted arrangement, with 
even a single nucleotide substitution in position c.2808. We previously showed that two 
founder mutations of Castilla y León, BRCA1 c.5153-1G>A and BRCA2 
c.5146_5149delTATG, were also located in such secondary structures [28]. Altogether 
these data, we can conclude that the double-hairpin structure of c.2808_2811del is a 
mutation hotspot. It is also worth mentioning that hairpin-loops #4, #5 and #8 have a high 
incidence of reported and “artificial” mutations (Table 2), suggesting that they could also 
be hotspots. However, the mutagenesis experiment did not generate c.2808_2811del as 
Mutazyme-II polymerase only introduced insertions and deletions of one nucleotide 
despite we almost doubled the indel rate described with this polymerase (10.1% vs. 5.5%). 
In any case, we should be cautious when interpreting these results since this assay does 
not reproduce the physiological conditions: first, Mutazyme-II is a modified prokaryotic 
polymerase; second, the supercoiled structure of the plasmid where the template is 
cloned may influence this process; and, third, the genomic and nucleosomal contexts may 
also play a role in the natural phenomenon of mutagenesis. Twenty different variants 
(three of them in two independent clones) of the mutagenesis experiment affected the 
same positions of reported variants but they consisted of different nucleotide changes, 
and three mutations produced the same nucleotide-change: one single-nucleotide 
substitution (c.2680G>A), one insertion (c.2957dup in two independent clones) and one 
deletion (c.2944del). Curiously, none of these three variants was placed in hairpin-loops 
suggesting that their occurrence is not probably related to the secondary structure of 
DNA. 
On the other hand, the most prevalent mutations of BRCA1 (c.68_69del) and BRCA2 
(c.5946delT), both of Ashkenazi origin, are located in a hairpin-loop structure and in a 
complex hairpin arrangement with multiple loops, respectively (Figure 4). Interestingly, 
c.68_69del has been proven to have at least three founder effects [35;36] suggesting that 
this sequence is also a mutation hotspot. The observation of a recurrent BRCA mutation 
with multiple origins has also been documented in BRCA2 c.8537delAG that was found in 
distinct populations with three differentiated haplotypes [37]. The authors suggested that 
the presence of repetitive sequences could allow for mismatching during replication. As 
expected, BRCA2 c.8537delAG also lies in a large loop (Figure 4).  
 In conclusion, the presence of several haplotypes linked to c.2808_2811del 
indicated that three independent events occurred. This might due to the presence of a 
mutation hotspots in this region that would justify its high frequency worldwide. This 
sequence lies within a double-hairpin-loop structure that we postulate as a mutation 
hotspot. The identification of recurrent mutations in a specific population allows the 
redefinition of the genetic screening strategy as well as a more accurate estimation of the 
risk associated with this mutation. 
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Fig. 1. Haplotype tree of eleven 13q polymorphic markers. The three main core haplotypes are 
in bold font and surrounded by squares. The markers used are ordered according to their position 
in the Ensembl Genome Browser. Asterisk indicates families where only the index case was 
available.  
 
Fig. 2. Geographic distribution of the 51 BRCA2-c.2808_2811del families analyzed and their 
associated haplotypes. The three different haplotypes are represented by squares (WCL), circles 
(ECL) and triangles (SoS). CN-428 and CN-565 are families with only the index case whose core 
haplotype could not be ascertained. 
 
Fig. 3. Quikfold prediction of the DNA secondary structure of the DNA fragment between 
nucleotides c.2714 and c.2902. Mutation c.2808_2811del is shown in hairpin #7. DNA variants 
detected in the mutagenesis experiment are indicated. Designation of DNA variants is based on 
the BRCA2 cDNA sequence NM_000059.1. Green squares highlight mutations that affect the same 
nucleotide of reported mutations but differ in the nucleotide change. Mutations that have been 
identified twice in two independent clones are shown in italics. Variants that have been detected 
in clones that contain more than one change are shown in bold type. 
 
Fig. 4. DNA secondary structure predictions with Quikfold of sequences flanking highly 
prevalent mutations: A) BRCA1-c.68_69del; B) BRCA2-c.5946delT; C) BRCA2-c.8537_8538delAG. 
Affected nucleotides of each variant are circled.  
 
Table 1. Clinical characteristics of the BRCA2- c.2808_2811delACAA families. 
Familya  ADxc,d,e  
Number of cancer cases in not tested relatives 
BC<50f BC>50f OC BOC MBC Other cancers (number) c, d 
BU-48 53 3 - - - - - 
BU-79 41, 41, 42, 44, 60OC - - - - - NHL 
BU-89 29 3 - - - - - 
BU-260 32 - - - - - Pancreas 
BU-265 0 (43) 2(1) - 1 - - - 
BU-385 29, 35 2 - - - - Gastric, leukemia, lung 
BU-389 52 1(1) - 1 - - CRC, gastric (2), leukemia  
BU-398 28 - - - - - Gastric 
BU-446 48, 62 OC 1 - - - - Larynx, renal 
BU-456 44 1 1(1) - - - CRC (2) 
BU-466 35-39bil, 43 - - - - - Esophagus, sarcoma 
BU-477 47 - 1 - - - Head and neck 
BU-732 54bil, 55 1 1 - - - Head and neck, leukemia, lung  
BU-852 58OC,39-52bil - 2 - - - Esophagus, lung, gastric, CRC (3) 
BU-855 36bil 1 1 - - - NHL, Endometrial, Prostate (2) 
BU-904 45-64bil 1 2 (1) - - - CNS, lung 
SA-1 37 3 1 - - - Pancreas (2), prostate (2) 
SA-2  40 1 1(1) - - - Pancreas,  prostate 
SA-3  43 5 - - - - - 
SA-4  30 - - - 1 - CNS, gastric 
SA-5  55 3 2 - - - CRC, lung, gastric, pancreas (2) 
SA-6 0 (32) 3 - 1 - - CNS, pancreas 
SA-7  46, 70 5(2) 7 1 - - - 
SA-8  48-52bil-49OC 1 4(1) - - - Pancreas 
SA-9 34 1 - 1 - - Pancreas, prostate (2) 
BI-167 76MBC - 1 - - - Lung 
M-110  46 2 2 - - - - 
M-171  65bil 1 - - - - Gastric, Prostate 
CN-59 e  32, 35, 40 2 - - - - Cervix, Prostate 
CN-87 48-53OC - - - - - Intestinal, Pancreas, Prostate 
CN-93 41, 46 3 - - - - CRC, Sarcoma 
CN-428 49OC 3 - 1 - - Leukemia 
CN-565 58MBC - - - - - - 
CN-827 
M-178 31 1 - - - - Prostate 
CN-877 69OC - - - - - - 
CN-1357 46, 49 - - - - 1 Mediastinum, Prostate 
ICO-61  26-30bil - 1 - - - - 
ICO-337  53OC - - - - - CRC, Endometrial (2) 
ICO-358 65 1 1 - - 1 Leukemia, LNH, Renal 
ICO-847  67OC  - 2 - - - Gastric (2), Head and Neck, Hepatic (2), Prostate 
ICO-1188 34-50bil - 1 - - - Bladder, Hepatic, Lung, Prostate 
VH-60 42, 58 1 2 - - - Prostate 
VH-209 36 2 1 - - - Peritoneal, Liver 
VH-400 29, 36bil, 53 2 - - - - Stomach 
SP-121 38, 50-52OC, 68OC - - - - - - 
SP-122 82 3 - - - - Lung 
SP-378 45 1 2 - - - Lung, Gastric 
V-44 / 
SP-395  30 - - 3 - - Leukemia, Lung 
V-156 42 - - 1 - - - 
V-309  29, 38, 39 - 1 - - - Prostate 
Z-195 28, 43, 37, 72 1 - - - - Prostate (2), Bladder 
a Samples were recruited in the following collaborating centers: Hospital Universitario de Burgos (16 BU families), Centro de Investigación del 
Cáncer in Salamanca (nine SA families), Centro Nacional de Investigaciones Oncológicas in Madrid (nine CN families), Institut Català d’Oncologia 
in L’Hospitalet (five ICO families), Hospital de la Santa Creu i Sant Pau in Barcelona (three SP families), Hospital Clínico San Carlos in Madrid (three 
M families), Hospital Universitario La Fe in Valencia (three V families), University Hospital Vall d’Hebron in Barcelona (three VH families), Hospital 
de Cruces in Barakaldo (one BI family) and Hospital Clínico Universitario Lozano Blesa in Zaragoza (one Z family).  b ADx:  age of diagnosis. Actual 
age is indicated between parentheses in aymptomatic carriers c Carriers or obligate carriers are underlined. d Type of cancer: BC, Breast Cancer; 
OC, Ovarian Cancer; BOC, Breast and Ovarian Cancer; MBC, Male Breast Cancer; bil, Bilateral Breast Cancer; NHL, Non-Hodking Lymphoma, CRC; 
Colorectal Cancer. e Patient CN-59 had cervix carcinoma at 38 years. f Number of bilateral BC cases are indicated between parentheses.  
Table 2. Summary of DNA variants reported in mutation databases and detected in the random 
mutagenesis experiment between hairpins 4 and 10.  
Hairpin-Loop cDNAa Databases Mutagenesis Nt / mutationb 
4 c.2719-c.2727 1 4 1.8 
Inter-sequence 4 c.2728-c.2738 3 3 1.8 
5 c.2739-c.2769 7 11 1.7 
Inter-sequence 5  c.2770-c.2776 1 2 2.3 
6 c.2777-c.2792 3 3 2.7 
7  c.2794-c.2825 13 5 1.8 
8 c.2830-c.2840 7 3 1.1 
9 c.2842-c.2871 5 6 2.7 
Inter-sequence 9 c.2872-c.2883 3 3 2.2 
10 c.2884-c.2895 0 3 4.0 
TOTALS 43 42 2.1 
a Nucleotide numbering is based on BRCA2 cDNA sequence NM_000059.1 where nucleotide 1 is the A of the ATG-
translation initiation codon. 
b Nucleotides per mutation. Rates below the average (2.1) are shown in bold type. 
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Supplemental Table S1. Haplotype reconstruction of five and six markers with the PHASE program from the 
genotype data of 75 control individuals. The haplotypes linked to c.2808_2811del (WCL, ECL and MC) are 
highlighted. 
Five markers1 
D13S1697- c.865A>C- c.1114C>A-c.3396A>G-c.3807T>C 
Six  markers1 
D13S1697-c.865A>C-c.1114C>A-c.3396A>G-c.3807T>C-D13S171 
Haplotype Frequency S.E Haplotype Frequency S.E 
2ACAT    0.2238   0.0115 2ACAT6      0.0975     0.0200 
2AAAT-WCL 0.1929    0.0080 2ACAT7 0.0912    0.0222 
2AAGT-ECL 0.1787   0.0141 2AAAC6 0.0863    0.0262 
2AAAC   0.1560   0.0112 2AAAT-WCL 0.0799    0.0287 
3AAGT  0.0933     0.0146 2AAGT6-ECL 0.0668     0.0102 
3ACAT-SoS 0.0522 0.0111 2AAAT7 0.0584 0.0261 
2CAAT    0.0186   0.0027 2AAAC7 0.0568    0.0187 
1AAAT    0.0171   0.0050 3AAGT7 0.0419   0.0156 
1AAGT  0.0109     0.0032 2AAGT7 0.0403    0.0137 
3AAAT     0.0098    0.0079 3AAGT6 0.0384    0.0154 
2ACAC     0.0020 0.0031 2AAAT2 0.0338    0.0054 
1ACAT  0.0013  0.0026 2AAGT2 0.0290    0.0073 
2AAGC   0.0013 0.0026 3AAGT2 0.0257     0.0049 
3ACAC  0.0007     0.0020 2ACAT8 0.0243     0.0101 
3AAAC    0.0349 0.0080 2AAGT8 0.0208  0.0072 
1AAAC  0.0040    0.0051 3ACAT8-SoS 0.0157     0.0088 
3CAGT    0.0013 0.0027 3ACAT6-SoS 0.0138    0.0067 
3AAGC    0.0011 0.0025 2ACAT2 0.0136     0.0096 
TOTAL: 18 HAPLOTYPES 1AAAT7 0.0124     0.0059 
 2AAAC2 0.0122     0.0060 
2AAAT8 0.0120    0.0050 
3ACAT7 0.0097    0.0074 
2AAAC3 0.0097    0.0049 
2CAAT6 0.0090     0.0083 
3AAAC2 0.0083  0.0055 
3AAAT7 0.0078     0.0066 
2AAAC8 0.0077    0.0052 
2CAAT7 0.0075     0.0079 
1AAAT6 0.0069     0.0051 
1AAGT6 0.0067     0.0000 
3AAGT8 0.0066     0.0042 
2ACAT5 0.0053    0.0040 
3AAAC7 0.0051    0.0076 
3AAAC8 0.0050    0.0055 
3ACAT2 0.0040    0.0049 
3AAAC6 0.0040     0.0044 
1AAGT2 0.0040     0.0033 
2AAAT5 0.0033    0.0033 
1AAAC2 0.0027    0.0033 
3ACAT5 0.0027     0.0033 
2AAGT5 0.0020     0.0031 
3AAGT3 0.0020     0.0031 
2AAAT3 0.0017     0.0029 
2CAAC7 0.0014     0.0028 
3AAAT6 0.0014     0.0028 
2CAGT6 0.0013    0.0029 
3AAAT8 0.0007     0.0020 
1ACAT6 0.0007     0.0020 
2ACGT7 0.0007     0.0020 
3CAGT6 0.0007    0.0020 
2ACAC8 0.0006     0.0020 
TOTAL: 51 HAPLOTYPES 
1 D13S1697 Alleles: 1, 229 bp; 2, 225 bp; 3, 221 bp. D13S171 alleles:  2, 205 bp; 3, 203; 5, 197; 6, 195 bp; 7, 193 bp; 8, 
191 bp. 
 
Supplemental Table S2. Current ages of asymptomatic BRCA2-c.2808_2811delACAA carriers.  
 
FAMILY 
Number of 
carriers 
3036delACAA+ (current age) 
<40 41-50 51-60 61-70 >71 
Female Male Female Male Female Male Female Male Female Male Female Male 
BU-48  1  38         
BU-79 2 2 18  44   52    90 
BU-260          66   
BU-265 2  40  43        
BU-385 2  26    53      
BU-398 4 2 26, 27 25  43 55, 59      
BU-456 2  21, 22          
BU-466  2  25    60 63    
BU-477 3 1 35 25 46        
BU-904 1  37          
SA-1 1 1 21 19         
SA-2 3  24,30    54      
SA-4 1  40          
SA-6 1  32          
SA-7 1  33          
BI-167 1      56      
M-110 2 (BPM)* 2 33 30 44* 50       
CN-59 2 3 19 40  48, 50   65    
CN-87 2  33, 35          
CN-877 1 1   46 44       
CN-
1357 1 1 27 30         
ICO-61  2  38      70   
ICO-337 1  33          
ICO-358 2   40  46       
ICO-847  1    45       
ICO-
1188 1  26          
VH-60 3  34,37    58      
SP-121 2 1 35 39     62    
V-44/ 
SP-395 1    43        
V-156 2 1 26, 30 24         
Z-195 1 3 35 33    51 / 59     
* BPM, Bilateral prophylactic Mastectomy.  
Supplemental Table S3. List of sequence variants detected in the random 
mutagenesis experiment and reported in patients in the mutation databases. 
List of BIC and 
UMD variants 1 HAIRPIN-LOOP 
RANDOM MUTAGENESIS 
DNA change1,2 Clone #3 
c.2635T>A   c.2633A>T 60 
c.2636_2637delCT   c.2634C>A 35 
c.2643A>G 
2 
c.2659G>A 32 
c.2653_2656delGACA c.2660A>T 6 
c.2657A>T c.2662A>G 7 
c.2657delA c.2668T>C 72 
c.2660A>G c.2670T>A 3 
  c.2676C>A 13 
c.2677C>T   c.2677delC 22 
c.2678A>G   c.2680G>A 15 
c.2680G>A   c.2681T>A 55 
c.2684delC   c.2683G>A 31 
    c.2683G>A 35 
    c.2685T>C 25 
    c.2687A>G 44 
c.2690A>G 
3 
c.2691A>T 28 
c.2691A>G c.2699A>G 37 
c.2698A>G c.2699A>T  14 
c.2701delC c.2701C>A 36 
  c.2702T>A 52 
  c.2703T>A 38 
  c.2703T>C 9 
  c.2706T>C 55 
  c.2707T>C 15 
c.2716A>G       
c.2719A>G 
4 
c.2720A>T 72 
  c.2720delA 22 
  c.2722delG 43 
  c.2725C>A 67 
c.2731delG   c.2728C>T 23 
c.2735C>T   c.2736A>C 24 
c.2735C>A   c.2737G>T 27 
c.2739C>T 
5 
c.2739C>G 27 
c.2743_2747delACTTG c.2744C>T 20 
c.2745_2746delTT c.2745T>A 54 
c.2751A>G c.2746T>A 21 
c.2755G>A c.2748T>C 60 
c.2758C>A c.2756A>G 25 
c.2760delC c.2762T>C 43 
  c.2763T>C 52 
  c.2768A>C 5 
  c.2768A>T 9 
  c.2769G>A 12 
c.2771A>T   c.2771A>G 1 
    c.2771A>G 64 
c.2780T>C 
6 
c.2777C>T 26 
c.2786T>C c.2783T>A 62 
c.2786dup c.2786delT 74 
c.2798delC 
7 
c.2804A>G 5 
c.2798_2799delCA c.2808A>G 3 
c.2798C>G c.2812G>T 12 
c.2803G>A c.2816C>T 67 
c.2803G>C c.2819A>G 54 
c.2805_2808delTAAA     
c.2808_2811delACAA     
c.2810_2811delAA     
c.2812_2815delGCAA     
c.2813C>A     
c.2817C>T     
c.2818C>T     
c.2821G>A     
c.2830A>T 
8 
c.2830A>G 12 
c.2833_ 2834ins TT c.2835delA 7 
c.2834_2835delAA c.2835A>G 52 
c.2836_2837delGA     
c.2836delG     
c.2836G>C     
c.2837A>G     
c.2842dup 
9 
c.2848G>A 2 
c.2849T>A c.2851C>T  38 
c.2854G>T c.2857G>T 37 
c.2860_2862delGAG c.2860G>T 22 
c.2862G>A c.2867A>G 40 
  c.2868A>T 50 
c.2872A>G   c.2873G>T 44 
c.2881C>T   c.2875G>A 25 
c.2883G>A   c.2882A>C 71 
  
10 
c.2886T>A  6 
  c.2893delA 50 
  c.2893A>C 56 
c.2899_2900delCT   c.2896A>G 42 
c.2899C>G   c.2898T>C 28 
    c.2899C>A 34 
    c.2900T>A 37 
    c.2902G>A 63 
c.2905C>T 
11 
c.2907A>G 52 
c.2918C>G c.2914A>C 54 
c.2919G>A c.2915A>C 67 
c.2926_ 2927delinsAT   c.2924T>C 56 
c.2927_2929delCCT   c.2927C>T 10 
c.2930_2940del11   c.2930T>A 41 
c.2944A>C   c.2932A>G 46 
c.2944delA   c.2934T>A 23 
c.2946A>G   c.2935A>T 49 
c.2956A>G   c.2938G>T 7 
c.2957_2958insG   c.2944delA 72 
c.2957dup   c.2946A>T 60 
c.2957A>T   c.2950G>T 63 
c.2957A>G   c.2957dup 67 
    c.2957dup 28 
c.2960A>T 12     
c.2965T>G     
c.2971A>G   c.2970G>T 74 
c.2977T>C       
c.2978G>A       
c.2979G>A       
c.2987T>G 13     
    c.2999T>A 28 
 
Nucleotide sequences of Forward (c.2610-c.2630) and Reverse primers (c.3008-c.3028) have been excluded from this 
table. 
1 Nucleotide numbering is based on BRCA2 cDNA sequence NM_000059.1 where nucleotide 1 is the A of the ATG-
translation initiation codon. Yellow squares denote mutations reported in the databases that have been replicated in the 
random mutagenesis experiment. Green squares indicate mutations that affect the same nucleotide in databases and 
mutagenesis experiment but with a different DNA change.  
2 Artificial mutations that have been identified in two independent clones are shown in bold and italics. 
3 Clones that contain more than one mutation are shown in bold type 
 
Supplemental figure S1. Estimation of 3036delACAA age in generations.  DMLE+ 2.3 results in 
the Spanish context (A.1 and A.2), in the East CYL haplotype (B.1 and B.2) and in the West CYL 
haplotype (C.1 and C.2). A growth rate of 0.124 (A.1, B.1, C.1 figures) or 0.19  (A.2, B.2, C.2 
figures) were considered for each analysis. The 95% confidence interval (CI) for each analysis is 
shown.  
Spain 
58 generations 
95% CI: 49-73 
Spain 
85 generations 
95% CI: 72-110 
ECL 
81 generations 
95% CI: 67-105 
WCL 
85 generations 
95% CI: 73-112 
A.1 A.2 
B.1 
C.1 
B.2 
C.2 
ECL  
55 generations 
95% CI: 45-71 
WCL  
55 generations 
95% CI: 45-68 
r=0.124 r=0.190 
1 
2 3 
4 
10 
11 
12 
13 
14 
5 
7 
6 
8 
9 
c.2808_2811del 
Forward primer 
Reverse primer 
Supplemental Figure S2. Quikfold prediction of the DNA secondary stucture of the DNA 
fragment between nucleotides c.2610 and c.3028 of the BRCA2 cDNA. Primers 11E-Fw and 
11F-Rev that were used for the random mutagenesis assay are indicated. 
